36
Participants
Start Date
June 11, 2020
Primary Completion Date
July 31, 2024
Study Completion Date
October 31, 2024
Patients will be randomized to receive EHP-101 or Placebo
EHP-101 or placebo will be taken once a day
Patients will be randomized to receive EHP-101 or Placebo
EHP-101 or placebo will be taken twice a day
Royal Prince Alfred Hospital, Camperdown
Westmead Hospital, Sydney
Footscray Hospital, Footscray
Royal Adelaide Hospital, Adelaide
Wellington Hospital, Wellington
Fiona Stanley Hospital, Murdoch
Griffith University, Gold Coast
Central Florida Pulmonary Group, Altamonte Springs
Life Clinical Trials, Margate
Novel Clinical Research Center, Miami
Cleveland Clinic, Cleveland
University of Minnesota, Minneapolis
Northwestern University, Chicago
Arizona Arthritis & Rheumatology Associates, P.C., Phoenix
Pacific Arthritis Care Center, Los Angeles
UCLA Division of Rheumatology, Los Angeles
Inland Rheumatology Clinical Trials, Upland
Care Access Research - Huntington, Huntington Beach
Yale University, New Haven
Rutgers, The State University of New Jersey, New Brunswick
Centro Reumatologico, Caguas
Mindful Medical Research, San Juan
University of Puerto Rico, Medical Sciences Campus, San Juan
Lead Sponsor
Emerald Health Pharmaceuticals
INDUSTRY